LAB news

Standard BioTools (LAB) has completed the sale of its microfluidics business to private equity firm Archimed. The spinoff, now named Biomark Scientific, operates as an independent entity focusing on genomic workflows.

Standard BioTools signed a deal to sell its Microfluidics segment to ARCHIMED in an effort to streamline operations. The divestiture represents a strategic move to focus on core life science tools.

Labcorp announced its executives will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference. This participation highlights the company's focus on engaging with the healthcare investment community.

Standard Biotools Inc. has entered into a definitive merger agreement with Treeline Biosciences Inc., with Treeline surviving as the combined entity. The transaction represents a significant consolidation in the life sciences tools sector.